These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2470 related articles for article (PubMed ID: 28167322)

  • 1. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
    Qu J; Yuan Z; Wang G; Wang X; Li K
    Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
    Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
    Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
    Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
    Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
    Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W; Ba G; Tang R; Li M; Lin H
    Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
    Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
    Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
    Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
    J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
    Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
    Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
    Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
    Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
    Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
    McElvaney OJ; Zaslona Z; Becker-Flegler K; Palsson-McDermott EM; Boland F; Gunaratnam C; Gulbins E; O'Neill LA; Reeves EP; McElvaney NG
    Am J Respir Crit Care Med; 2019 Dec; 200(11):1381-1391. PubMed ID: 31454256
    [No Abstract]   [Full Text] [Related]  

  • 16. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
    Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
    Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis.
    Kaufmann B; Kui L; Reca A; Leszczynska A; Kim AD; Booshehri LM; Wree A; Friess H; Hartmann D; Broderick L; Hoffman HM; Feldstein AE
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):751-767. PubMed ID: 35787975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
    Kammoun HL; Allen TL; Henstridge DC; Barre S; Coll RC; Lancaster GI; Cron L; Reibe S; Chan JY; Bensellam M; Laybutt DR; Butler MS; Robertson AAB; O'Neill LA; Cooper MA; Febbraio MA
    Mol Metab; 2018 Apr; 10():66-73. PubMed ID: 29478918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Coll RC; Robertson AA; Chae JJ; Higgins SC; Muñoz-Planillo R; Inserra MC; Vetter I; Dungan LS; Monks BG; Stutz A; Croker DE; Butler MS; Haneklaus M; Sutton CE; Núñez G; Latz E; Kastner DL; Mills KH; Masters SL; Schroder K; Cooper MA; O'Neill LA
    Nat Med; 2015 Mar; 21(3):248-55. PubMed ID: 25686105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 124.